盐酸苯达莫司汀乙酯水解杂质 | 41515-13-3

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 盐酸苯达莫司汀乙酯水解杂质
• 英文名称: N-Desmethylbendamustine
• 英文别名: 4-[6-[bis(2-chloroethyl)amino]-1H-benzimidazol-2-yl]butanoic acid
• CAS: 41515-13-3
• 化学式: C₁₅H₁₉Cl₂N₃O₂
• 分子量: 344.2
• InChiKey: BPZIKXXNXMYQPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  69.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• ORAL BENDAMUSTINE FORMULATIONS
  申请人：TUBE Pharmaceuticals GmbH

  公开号：US20200246312A1

  公开（公告）日：2020-08-06

  The present invention relates to an oral pharmaceutical composition comprising bendamustine in combination with a modified cyclodextrin, such as, e.g., methyl-ß-cyclodextrin or hydroxypropyl-ß-cyclodextrin. It has surprisingly been found in the context of the invention that such compositions exhibit a greatly improved oral bioavailability, which renders them particularly advantageous for oral therapeutic application, e.g., in the treatment of cancer.
• [EN] COMBINATION OF CD37 ANTIBODIES WITH BENDAMUSTINE<br/>[FR] COMBINAISON D'ANTICORPS CD37 AVEC LA BENDAMUSTINE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013160396A1

  公开（公告）日：2013-10-31

  The present invention relates to immunotherapies that are based on depletion of CD37-positive cells such as B-cells. The present invention provides methods for reduction of CD37-positive cells such as B-cells in an individual/ patient using a combination of CD37 antibody /antibodies and bendamustine. The combination of CD37 antibodies and bendamustine is shown to have a synergistic effect. The application further provides materials and methods for treatment of diseases involving aberrant B-cell activity.